Skip to main content

Table 1 Characteristics of the studies and their populations included in the review

From: Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis

First author

Design

Year

Country

Population

Infection type—bacteria

No. of screened

No. of ESBL-PE BSIs (%)

No. of BSIs caused death

No. of ESBL-PE BSIs caused death (%)

ESBL detection method

ESBL-PE only

 Wang [31]

MC retrospective cohort

2011

Taiwan, China

Adults with solid or hematological malignancy

E. coli and Klebsiella

351

113 (32.2%)

35

35 (31.0%)

MicroScan

 Wu [15]

SC prospective cohort

2012

Taiwan, China

Adults with solid or hematological malignancy

E. coli

97

39 (40.2%)

10

10 (25.6%)

Disk diffusion

 Kang [17]

MC retrospective cohort

2013

Korea

Adults with solid malignancy

E. coli

92

36 (39.1%)

6

6 (16.7%)

Microdilution or disk diffusion

 Gudiol [29]

MC retrospective cohort

2017

Spain

Adults with acute leukemia and neutropenia

E. coli, Klebsiella, and Enterobacter cloacae

NR

425

65

65 (15.3%)

Disk diffusion

 Cattaneo [23]

MC prospective cohort

2018

Germany

Adults with hematological malignancy

E. coli, Klebsiella, and other Enterobacter spp

137

61 (44.5%)

10

10 (16.4%)

Microdilution

 Benanti [32]

SC retrospective cohort

2019

USA

Adults with hematological malignancy

E. coli

NR

103

11

11 (10.7%)

NR

ESBL-PE and non-ESBL-PE

 Trecarichi [13]

SC retrospective cohort

2009

Italy

Adults and children with hematological malignancy

E. coli

107

26 (24.3%)

13

11 (42.3%)

Disk diffusion

 Gudiol [27]

SC prospective cohort

2010

Spain

Adults and children with solid or hematological malignancy

E. coli

531

17 (3.2%)

29

6 (35.3%)

MicroScan

 Cornejo-Juarez [40]

Case–control study

2012

Mexico

Adults and children with hematological malignancy

E. coli

670

100 (14.9%)

102

51 (51%)

MicroScan

 Kang [14]

MC retrospective cohort

2012

Korea

Adults with hematological malignancy

E. coli and Klebsiella

142

29 (20.4%)

29

13 (44.8%)

Microdilution or disk diffusion

 Ha [16]

SC retrospective cohort

2013

Korea

Adults with solid or hematological malignancy

E. coli

350

95 (27.1%)

52

21 (22.1%)

Disk diffusion

 Kim [18]

SC retrospective cohort

2013

Korea

Adults with hematological malignancy and FN

E. coli and Klebsiella

96

23 (24.0%)

8

4 (17.4%)

MicroScan

 Metan [34]

SC retrospective cohort

2013

Turkey

Adults and children with hematological malignancy

E. coli, Klebsiella, and Enterobacter cloacae

154

40 (26.0%)

30

5 (12.5%)

NR

 Bodro [19]

SC prospective cohort

2014

Spain

Adults with solid or hematological malignancy

Klebsiella and other Enterobacter spp

392

19 (4.8%)

18

4 (21.1%)

Disk diffusion

 Kim [28]

SC prospective cohort

2014

Korea

Adults and children with solid or hematological malignancy

Enterobacter spp

203

31 (15.3%)

34

6 (19.4%)

Disk diffusion

 Han [20]

SC retrospective cohort

2015

Korea

Children with solid or hematological malignancy and FN

E. coli and Klebsiella

59

21 (35.6%)

3

1 (4.8%)

VITEK®2 automated system

 Cattaneo [21]

MC prospective cohort

2016

Italy

Adults with acute leukaemia

Enterobacter spp

433

36 (8.3%)

37

5 (13.9%)

Microdilution or disk diffusion

 Ma [22]

SC retrospective cohort

2017

China

Adults with hematological malignancy

E. coli

168

97 (57.7%)

21

15 (15.5%)

Disk diffusion

 Çeken [24]

SC retrospective cohort

2018

Turkey

Adults with solid or hematological malignancy

E. coli and Klebsiella

122

70 (57.4%)

31

23 (32.9%)

VITEK®2 automated system

 Islas-Muñoz [25]

SC prospective cohort

2018

Mexico

Adults with solid or hematological malignancy

E. coli, Klebsiella, and Enterobacter spp

496

123 (24.8%)

89

37 (30.1%)

Disk diffusion

 Ben-Chetrit [42]

SC retrospective cohort

2019

Israel

Adults with solid or hematological malignancy

E. coli and Klebsiella

88

26 (19.5%)

17

6 (7.5%)

NR

 Isendahl [26]

Case–control study

2019

Sweden

Adults and children with solid or hematological malignancy

E. coli and Klebsiella

945

238 (25.2%)

107

45 (18.9%)

NR

 Kim [35]

SC prospective cohort

2019

Korea

Adults with solid or hematological malignancy and FN

E. coli and Klebsiella

179

23 (12.8%)

51

8 (34.8%)

MicroScan

 Namikawa [30]

Case–control study

2019

Japan

Adults with solid or hematological malignancy

E. coli, Klebsiella, and Enterobacter spp

65

42 (64.6%)

13

9 (21.4%)

NR

 Zhang [33]

SC retrospective cohort

2019

China

Adults with solid or hematological malignancy

E. coli

324

160 (49.3%)

71

39 (24.4%)

VITEK®2 automated system

  1. ESBL-PE extended-spectrum β-lactamase-producing Enterobacteriaceae, BSI bloodstream infection, SC single-center, MC multicenter, NR not reported, FN febrile neutropenia